Feng Tian, Ph.D., is the Chairman of the Board, President and CEO of Ambrx, and has been with the company about 17 years. Formerly Ambrx’s Chief Scientific Officer, Dr. Tian has overseen the company’s research and development. He led team to establish various technology programs such as the EuCODE platform and antibody drug conjugate platform. Prior to Ambrx, Dr. Tian conducted his post-doctoral study at The Scripps Research Institute under Peter Schultz. Dr. Tian received his Ph.D. in chemistry from the University of Florida and his B.S. in chemistry from Peking University.